Literature DB >> 31211471

Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders.

Mark S Moehle1, P Jeffrey Conn1.   

Abstract

Acetylcholine (ACh) released from cholinergic interneurons acting through nicotinic and muscarinic acetylcholine receptors (mAChRs) in the striatum have been thought to be central for the potent cholinergic regulation of basal ganglia activity and motor behaviors. ACh activation of mAChRs has multiple actions to oppose dopamine (DA) release, signaling, and related motor behaviors and has led to the idea that a delicate balance of DA and mAChR signaling in the striatum is critical for maintaining normal motor function. Consistent with this, mAChR antagonists have efficacy in reducing motor symptoms in diseases where DA release or signaling is diminished, such as in Parkinson's disease and dystonia, but are limited in their utility because of severe adverse effects. Recent breakthroughs in understanding both the anatomical sites of action of ACh and the mAChR subtypes involved in regulating basal ganglia function reveal that the M4 subtype plays a central role in regulating DA signaling and release in the basal ganglia. These findings have raised the possibility that sources of ACh outside of the striatum can regulate motor activity and that M4 activity is a potent regulator of motor dysfunction. We discuss how M4 activity regulates DA release and signaling, the potential sources of ACh that can regulate M4 activity, and the implications of targeting M4 activity for the treatment of the motor symptoms in movement disorders.
© 2019 International Parkinson and Movement Disorder Society. © 2019 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  basal ganglia; cholinergic; motor deficits; movement disorders; muscarinic

Mesh:

Substances:

Year:  2019        PMID: 31211471      PMCID: PMC6699902          DOI: 10.1002/mds.27740

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  87 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  An allosteric enhancer of M₄ muscarinic acetylcholine receptor function inhibits behavioral and neurochemical effects of cocaine.

Authors:  Ditte Dencker; Pia Weikop; Gunnar Sørensen; David P D Woldbye; Gitta Wörtwein; Jürgen Wess; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2012-05-31       Impact factor: 4.530

Review 3.  Muscarinic acetylcholine receptors.

Authors:  Masaru Ishii; Yoshihisa Kurachi
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

4.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.

Authors:  A I Levey; C A Kitt; W F Simonds; D L Price; M R Brann
Journal:  J Neurosci       Date:  1991-10       Impact factor: 6.167

Review 5.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

6.  Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.

Authors:  Samira Ztaou; Nicolas Maurice; Jeremy Camon; Gaëlle Guiraudie-Capraz; Lydia Kerkerian-Le Goff; Corinne Beurrier; Martine Liberge; Marianne Amalric
Journal:  J Neurosci       Date:  2016-08-31       Impact factor: 6.167

7.  Dystonia in Parkinson's disease: clinical and pharmacological features.

Authors:  W H Poewe; A J Lees; G M Stern
Journal:  Ann Neurol       Date:  1988-01       Impact factor: 10.422

8.  Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia.

Authors:  Karin Mente; Nancy A Edwards; Demelio Urbano; Abhik Ray-Chaudhury; Diego Iacono; Ana Tereza Di Lorenzo Alho; Eduardo Joaquim Lopes Alho; Edson Amaro; Silvina G Horovitz; Mark Hallett
Journal:  Mov Disord       Date:  2018-03-06       Impact factor: 10.338

Review 9.  Muscarinic receptor antagonists in the treatment of overactive bladder.

Authors:  C R Chapple
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

10.  Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release.

Authors:  Daniel J Foster; Jermaine M Wilson; Daniel H Remke; M Suhaib Mahmood; M Jashim Uddin; Jürgen Wess; Sachin Patel; Lawrence J Marnett; Colleen M Niswender; Carrie K Jones; Zixiu Xiang; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuron       Date:  2016-09-08       Impact factor: 17.173

View more
  8 in total

Review 1.  Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches.

Authors:  Nicolaas I Bohnen; Alison J Yarnall; Rimona S Weil; Elena Moro; Mark S Moehle; Per Borghammer; Marc-André Bedard; Roger L Albin
Journal:  Lancet Neurol       Date:  2022-02-04       Impact factor: 44.182

2.  Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Authors:  Matthew Spock; Trever R Carter; Katrina A Bollinger; Changho Han; Logan A Baker; Alice L Rodriguez; Li Peng; Jonathan W Dickerson; Aidong Qi; Jerri M Rook; Jordan C O'Neill; Katherine J Watson; Sichen Chang; Thomas M Bridges; Julie L Engers; Darren W Engers; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Aaron M Bender
Journal:  ACS Med Chem Lett       Date:  2021-08-02       Impact factor: 4.632

Review 3.  Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?

Authors:  Matthew J Barrett; Lana Sargent; Huma Nawaz; Daniel Weintraub; Elvin T Price; Allison W Willis
Journal:  Mov Disord Clin Pract       Date:  2021-10-08

Review 4.  Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sean P Moran; James Maksymetz; P Jeffrey Conn
Journal:  Trends Pharmacol Sci       Date:  2019-11-08       Impact factor: 14.819

5.  Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy.

Authors:  Mark S Moehle; Aaron M Bender; Jonathan W Dickerson; Daniel J Foster; Aidong Qi; Hyekyung P Cho; Yuping Donsante; Weimin Peng; Zoey Bryant; Kaylee J Stillwell; Thomas M Bridges; Sichen Chang; Katherine J Watson; Jordan C O'Neill; Julie L Engers; Li Peng; Alice L Rodriguez; Colleen M Niswender; Craig W Lindsley; Ellen J Hess; P Jeffrey Conn; Jerri M Rook
Journal:  ACS Pharmacol Transl Sci       Date:  2021-08-02

6.  Subtle changes in striatal muscarinic M1 and M4 receptor expression in the DYT1 knock-in mouse model of dystonia.

Authors:  Franziska Richter; Laura Klein; Christin Helmschrodt; Angelika Richter
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

Review 7.  Two Players in the Field: Hierarchical Model of Interaction between the Dopamine and Acetylcholine Signaling Systems in the Striatum.

Authors:  Jaromir Myslivecek
Journal:  Biomedicines       Date:  2021-01-01

Review 8.  Parkinson's disease and translational research.

Authors:  Elisabeth Dinter; Theodora Saridaki; Leonie Diederichs; Heinz Reichmann; Björn H Falkenburger
Journal:  Transl Neurodegener       Date:  2020-12-01       Impact factor: 8.014

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.